CorMedix CRMD Balance Sheet Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $179.08M+22.8% | $145.83M+195% | $49.48M-69.0% | $159.41M+140% | $66.39M+62.9% | ||
| $0-100% | $3.69M-48.9% | $7.22M-77.0% | $31.4M+180% | $11.22M+1.6% | ||
| $154.81M-9.6% | $171.23M+8.0% | $158.57M+270% | $42.91M-21.4% | $54.61M+5.7% | ||
| $30.73M+3.4% | $29.72M+2.8% | $28.92M+200% | $9.63M+28.7% | $7.49M-1.5% | ||
| $383.11M+4.4% | $367.05M+41.4% | $259.54M+4.6% | $248.06M+71.2% | $144.86M+26.4% | ||
| $6.17M+3.5% | $5.96M+37.1% | $4.35M+165% | $1.64M-5.0% | $1.73M-5.5% | ||
| $30M0.0% | $30M+71.3% | $17.52M— | —— | —— | ||
| $368.77M-2.7% | $379.07M+48.9% | $254.61M+14,531% | $1.74M-2.9% | $1.79M-2.8% | ||
| $815.64M-1.3% | $826.14M+10.0% | $750.86M+197% | $252.6M+68.9% | $149.58M+25.9% | ||
| $12.83M+62.7% | $7.88M-61.5% | $20.45M+252% | $5.82M+201% | $1.93M+12.4% | ||
| $128.78M-26.1% | $174.27M+30.4% | $133.64M+321% | $31.71M-7.8% | $34.39M+1.6% | ||
| $378.59M-10.0% | $420.84M+11.7% | $376.73M+1,078% | $31.97M-7.9% | $34.69M+1.5% | ||
| 160M0.0% | 160M0.0% | 160M0.0% | 160M0.0% | 160M0.0% | ||
| -$137.97M+21.9% | -$176.58M+7.4% | -$190.6M+36.3% | -$299.16M+6.2% | -$318.99M+6.1% | ||
| $437.05M+7.8% | $405.31M+8.3% | $374.13M+69.6% | $220.63M+92.0% | $114.89M+35.7% | ||
| $815.64M-1.3% | $826.14M+10.0% | $750.86M+197% | $252.6M+68.9% | $149.58M+25.9% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are CorMedix's total assets?
- CorMedix (CRMD) holds $815.6M in total assets, up 445.3% year over year.
- How much cash does CorMedix have?
- CorMedix holds $179.1M in cash and equivalents.
- Can CorMedix cover its short-term obligations?
- Its current ratio is 2.98 — current assets exceed current liabilities.
- Where does CorMedix's balance sheet data come from?
- Every line is extracted from CorMedix's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
